Effect of ubenimex on a CD5-CD13+ CLL patient with an aggressive clinical course.
Horikoshi
A
A
Irie
T
T
Ishizuka
H
H
Ohkubo
T
T
Hosokawa
Y
Y
Sawada
S
S
D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018826:CD13 Antigens; D018956:CD5 Antigens; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male
D000903:Antibiotics, Antineoplastic; D018956:CD5 Antigens; D018826:CD13 Antigens; D007930:Leucine; C012211:ubenimex